Methods and Compositions for the Treatment of Metabolic Disorders and Diseases

a metabolic disorder and composition technology, applied in the field of metabolic disorders and diseases, can solve the problems of harmful side effects, hypoglycemia shock, and patients rarely attaining ideal glucose levels by insulin injection, and achieve the effect of treating

Inactive Publication Date: 2020-02-20
NGM BIOPHARMLS
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a treatment method for reducing glucose levels, increasing insulin sensitivity and decreasing insulin resistance, as well as improving glucose tolerance and pancreatic function. The treatment also results in reduced triglyceride, cholesterol, and blood pressure levels, as well as decreasing intimal thickening of blood vessels and reducing body mass or weight gain.

Problems solved by technology

However, such patients rarely attain ideal glucose levels by insulin injection (Turner, R. C. et al.
Furthermore, prolonged elevation of insulin levels can result in detrimental side effects such as hypoglycemic shock and desensitization of the body's response to insulin.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and Compositions for the Treatment of Metabolic Disorders and Diseases
  • Methods and Compositions for the Treatment of Metabolic Disorders and Diseases
  • Methods and Compositions for the Treatment of Metabolic Disorders and Diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0287]The following is a description of various methods and materials used in the studies herein.

[0288]Animals.

[0289]db / db mice were purchased from The Jackson Laboratory (Bar Harbor, Me.), Mice were kept in accordance with welfare guidelines under controlled light (12 hr light and 12 hr dark cycle, dark 6:30 pm-6:30 am), temperature (22±4° C.) and humidity (50%+20%) conditions. They had free access to water (autoclaved distilled water) and were fed ad libitum on a commercial diet (Harlan Laboratories, Indianapolis, Ind., Irradiated 2018 Teklad Global 18% Protein Rodent Diet) containing 17 kcal % fat, 23 kcal % protein and 60 kcal % carbohydrate. For diet-induced obesity, C57BL6 / J mice (Jackson Laboratory) were maintained on a high-fat diet (D12492, Research Diet, New Brunswick, N.J. USA) containing 60 kcal % fat, 20 kcal % protein and 20 kcal % carbohydrate for 16-20 weeks. All animal studies were approved by the NGM Institutional Animal Care and Use Committee.

[0290]DNA and Amino A...

example 2

[0309]The following is a description of studies showing the glucose lowering activity of various sequence variants of FGF19 and FGF21, and FGF19 / FGF21 fusion constructs.

[0310]FIG. 2 illustrates exemplary FGF19 / FGF21 fusion constructs, and the segments from each of FGF19 and FGF21 present in the fusion peptides. These peptides were analyzed for glucose lowering activity and statistically significant lipid elevating or increasing activity (Table 1-9, FIGS. 1 and 9, and the Sequence Listing).

[0311]Mice (db / db) were injected with viral vector expressing FGF19, FGF21 or variants, and analyzed after injection. Glucose-lowering activity of each sequence is represented by a “+” symbol (a “−” symbol means no glucose lowering activity, a “+ / −” symbol means variants retain minimal glucose-lowering activity); lipid elevating activity is represented by a “+” symbol (a “−” symbol means no lipid elevating activity, a “+ / −” symbol means variants retain minimal lipid-elevating activity, FIG. 2).

[031...

example 3

[0313]The following is a description of studies showing that variants M5, M1, M2 and M69 are not tumorigenic, as determined by HCC formation, and that variants M5, M2 and M69 also do not reduce lean muscle and fat mass.

[0314]Animals (db / db) were injected with AAV vectors expressing FGF19, FGF21, M5, M1, M2, or M69, or injected with saline, and analyzed 6 months after injection. The data indicate that variants M5, M1, M2, and M69 did not induce HCC formation significantly (FIGS. 5A-5C).

[0315]Animals (db / db mice) were also injected with viral vector expressing FGF19, FGF21, M5, M1, M2 or M69, or injected with saline, and analyzed 6 months after injection for the effect of on lean mass and fat mass. The data indicate that M5, M2 and M69 peptides did not cause a statistically significant reduction in lean mass or fat mass, in contrast to FGF21, and that M1 peptide reduces lean mass (FIGS. 6A-6C).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 15 / 313,528, filed Nov. 22, 2016, which is a U.S. National Stage Application under 35 U.S.C. § 371 of International Patent Application No. PCT / US2015 / 032581, filed May 27, 2015, which claims the benefit of priority to U.S. Ser. No. 62 / 004,043 filed May 28, 2014, each of which is incorporated herein by reference in its entirety.FIELD[0002]Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics) having glucose lowering activity, and methods for and uses of the variants and fusions in treatment of hyperglycemia and other disorders.INTRODUCTION[0003]Diabetes mellitus is a debilitating metabolic disease caused by abse...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/18C07K14/50
CPCC12N15/62A61K38/1825C07K14/50A61K38/00G01N2400/00
Inventor LING, LEILINDHOUT, DARRIN ANTHONY
Owner NGM BIOPHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap